Perspective Therapeutics, Inc. (CATX) AMEX
3.58
-0.085(-2.32%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.58
-0.085(-2.32%)
Currency In USD
| Previous Close | 3.66 |
| Open | 3.64 |
| Day High | 3.71 |
| Day Low | 3.56 |
| 52-Week High | 6.16 |
| 52-Week Low | 1.96 |
| Volume | 1.01M |
| Average Volume | 1.41M |
| Market Cap | 278.1M |
| PE | -2.55 |
| EPS | -1.41 |
| Moving Average 50 Days | 4.1 |
| Moving Average 200 Days | 3.62 |
| Change | -0.06 |
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
GlobeNewswire Inc.
Feb 17, 2026 12:00 PM GMT
SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today annou
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Feb 02, 2026 1:35 PM GMT
SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in 2026, as well as regulatory engagementVMT-α-NET